Healthcare / Pharmaceutical RetailersHKSE
$0.26
+0.00 (+1.96%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $8.0M · quality 33.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$232M
P/E
13.0x
↓EV/EBITDA
9.3x
↓ROE
2.9%
↑Gross Margin
24.6%
↓Debt/Equity
0.80
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-2.6%
FCF CAGR
—
FCF margin
8.8%
FCF / Net income
6.16x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.10B · net income $15.7M · FCF $96.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.10B | $1.10B | $876.0M | $1.20B | $1.19B |
| Net Income | $15.7M | $15.7M | $3.2M | $297.3M | $43.8M |
| EBITDA | $63.4M | $63.4M | $41.2M | $361.0M | $79.7M |
| EPS | — | — | 0.00 | 0.38 | 0.06 |
| Gross Margin | 24.6% | 24.6% | 26.6% | 26.8% | 22.0% |
| Operating Margin | 3.6% | 3.6% | 3.2% | 10.7% | 5.8% |
| Net Margin | 1.4% | 1.4% | 0.4% | 24.8% | 3.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.80 | 0.80 | 0.69 | 0.38 | 1.16 |
| Current Ratio | 1.40 | 1.40 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $96.5M | $96.5M | $-78.9M | $8.0M | $-53.6M |
| Returns | |||||
| ROE | 2.9% | 2.9% | 0.7% | 55.4% | 14.9% |
| Valuation | |||||
| P/E | 13.00 | 13.00 | 857.50 | 12.00 | 38.17 |
| EV/EBITDA | 9.31 | 9.31 | 72.35 | 10.40 | 25.90 |
| P/B | 0.43 | 0.43 | 5.61 | 6.69 | 6.12 |
| Growth & Yield | |||||
| Revenue Growth | 25.2% | 25.2% | -26.9% | 1.1% | — |
| EPS Growth | — | — | -98.9% | 533.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-40.9%
Start / end P/E
n/dx → n/dx
EPS bridge
0.00 → n/d
Residual
-40.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.